A Phase 1 interventional study of 64Cu-FBP8 and PET-CT imaging in Pulmonary Embolism, Deep Vein Thrombosis and Venous Thromboembolism, sponsored by Peter Caravan. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Peter Caravan · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.
Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 151st largest by enrollment of the 166 interventional ones that give a count, is one of 10 that started in 2019, is one of 14 in phase 1, and was the 153rd registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 21+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Angiodynamics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 38 · Phase 4 21
First in 1999; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 142 across the 166 interventional studies, 286 across the 68 observational. Of the 169 that completed or were terminated, 76 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 236 have an industry lead sponsor. The 10 most frequent:
Peter Caravan is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Peter Caravan has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
17 of the studies in Pulmonary Embolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591118Phase 3NYU Langone HealthPulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy | 2027-03-29 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 236 studies in Pulmonary Embolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).
Venous thromboembolism (VTE) is one of the most common causes of death in the United States, resulting in more than 100,000 deaths annually. Current diagnostic techniques rely on indirect measures of clot for diagnosis and therefore suffer from the problems of both under and overdiagnosis and cannot always be performed on patients with renal failure and lung disease. In this study, we will use the novel fibrin-specific probe 64CU-FBP8 (Copper-64 labeled fibrin binding probe 8) for PET imaging of fresh blood clots in PE and DVT. Our long-term goal is to establish a novel thrombus body scan (TBS) using 64CU-FBP8 for PET imaging to overcome the limitations of indirect venous thromboembolism diagnosis, and, with one single test, provide a total-body assessment of fresh intravascular clot.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
Drug: 64Cu-FBP8 · Diagnostic Test: PET-CT imaging
Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
Location of the Thrombus Within the Lungs
To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.
Time frame: 72 hours
Location of Clot Burden Measurements Within the Thigh
To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.
Time frame: 72 hours
Assessment of 64Cu-FBP8 Fibrin Activity in the Pelvic Veins and Upper Extremity
The presence or absence of blood clots as assessed by high 64Cu-FBP8 fibrin activity in the pelvic veins and upper extremities will be reported.
Time frame: 4 hours
Correlation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer
Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer. Outcome measure is the value of the Pearson correlation coefficient .
Time frame: 4 hours
Overall Clot Burden Within the Lungs
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs. This is reported in 4 different ways: 1. TBRmean of the PE which is the ratio of the mean PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 2. TBRmax of the PE which is the ratio of the maximum PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 3. SUVmean of the PE which is the mean standardized uptake value (SUV) in the pulmonary embolus (clot) 4. SUVmax of the PE which is the maximum standardized uptake value (SUV) in the pulmonary embolus (clot)
Time frame: 4 hours
Overall Clot Burden Within the Thigh
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh. This is reported as: TBRmean of the thrombus which is the ratio of the mean PET signal in the thrombus within the thigh divided by the mean PET signal in the blood pool
Time frame: 4 hours
Participants were recruited between May 2018 and August 2022 based on a PE diagnosis confirmed by CT pulmonary angiogram (CTPA).
| Milestone | Acute Pulmonary Embolism |
|---|---|
| Started | 6 |
| Completed | 5 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.
| Participants | Acute Pulmonary Embolism |
|---|---|
| Blood clots in same left-right lung location in PET and CTPA | 2 |
| Blood clots in same left-right lung location in PET as in CTPA and on the other side | 2 |
| No blood clots in PET | 1 |
To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.
| Participants | Acute Pulmonary Embolism |
|---|---|
| No evidence for clots | 5 |
| Evidence for clots | 0 |
The presence or absence of blood clots as assessed by high 64Cu-FBP8 fibrin activity in the pelvic veins and upper extremities will be reported.
| Participants | Acute Pulmonary Embolism |
|---|---|
| No evidence for clots | 5 |
| Evidence for clots | 0 |
Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer. Outcome measure is the value of the Pearson correlation coefficient .
| Pearson correlation coefficient | Acute Pulmonary Embolism |
|---|---|
| Correlation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer | 0 |
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs. This is reported in 4 different ways: 1. TBRmean of the PE which is the ratio of the mean PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 2. TBRmax of the PE which is the ratio of the maximum PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 3. SUVmean of the PE which is the mean standardized uptake value (SUV) in the pulmonary embolus (clot) 4. SUVmax of the PE which is the maximum standardized uptake value (SUV) in the pulmonary embolus (clot)
| Unitless ratio | Acute Pulmonary Embolism |
|---|---|
| TBRmean of the PE | 15.07 (10.86 to 22.35) |
| TBRmax of the PE | 23.23 (14.05 to 31.66) |
| SUVmean of the PE | 1.420 (0.708 to 1.743) |
| SUVmax of the PE | 2.098 (1.497 to 2.499) |
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh. This is reported as: TBRmean of the thrombus which is the ratio of the mean PET signal in the thrombus within the thigh divided by the mean PET signal in the blood pool
| Unitless ratio | Acute Pulmonary Embolism |
|---|---|
| Overall Clot Burden Within the Thigh | 0 ± 0 |
Collected over After 64Cu-FBP8 injection, during PET imaging, and 24 hours monitoring. The all-cause mortality is based on the last follow-up after 12 months, including the participant who withdrew from the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acute Pulmonary Embolism | 2/6 (33.3%) | 0/6 (0%) | 0/6 (0%) |
Including all recruited participants.
| Age, Continuous(years) | Acute Pulmonary Embolism |
|---|---|
| Mean | 61.8 (42 to 81) |
| Sex: Female, Male(Participants) | Acute Pulmonary Embolism |
|---|---|
| Female | 3 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | Acute Pulmonary Embolism |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Acute Pulmonary Embolism |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| D-dimer(ng/ml) | Acute Pulmonary Embolism |
|---|---|
| Mean | 2814 (290 to 10000) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Jul 2022, 38 months.
Results were first posted in Mar 2026, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Copper Cu 64 FBP8